Prostate News Archive
14-Nov-2006
Aeterna prostate cancer drug shows promise (Pharmaceutical Business Review)
Aeterna Zentaris has presented detailed positive phase II results in hormone-dependent, inoperable prostate cancer for its compound ozarelix. Dendreon completes FDA filing for prostate-cancer drug (Seattle Times)
Dendreon said Monday it has submitted the final portion of its application to the Food and Drug Administration for approval to market its prostate cancer drug in the U.S. Scientists Discover Way To Block Growth Of Prostate Cancer Cells (Science Daily)
Scientists have discovered for the first time a specific biochemical pathway by which the sex hormone, androgen, increases levels of harmful chemicals called reactive oxygen species (ROS) in the prostate gland that play a role in the development of prostate cancer, the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Prague heard on Wednesday.
Back to Prostate News Archive
